Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Deficiency of Hv1 Proton Channel Enhances Macrophage Antigen Presentation and Anti-Tumor Responses in Glioma 4365
Zheng, Jiaying, Wang, Lingxiao , Wan, Yushan , Johnson, Aaron J. , Wu, Long‐Jun , Wu, Long-Jun , Zhao, Shunyi , Ayasoufi, Katayoun , Goddery, Emma N. , Strege, Peter R. , Zhang, Wenjing, Xie, Manling , Beyder, Arthur , Johnson, Aaron J.

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.2059 Get It

Abstract Description In the tumor microenvironment of glioblastoma, myeloid cells act as a double-edged sword—they are a major cellular component suppressing the immune response while serving as a promising therapeutic target. Our study sheds light on the voltage-gated proton channel Hv1, predominantly expressed in myeloid cells, as a pivotal regulator of their physiological functions. Elevated Hv1 expression correlates strongly with poor prognosis in glioblastoma patients, underscoring its clinical significance. Using a glioma mouse model, we demonstrated that Hv1 depletion markedly extended survival. To overcome the limitations of existing tools, we engineered novel transgenic mouse lines optimized for Hv1 research. Our findings revealed tumor-induced Hv1 upregulation, with glioma-associated macrophages identified as the principal contributors. Crucially, we identified that Hv1 in infiltrating macrophages as the major driver of survival phenotype differences. Through a multi-faceted approach combining in vivo two-photon imaging, spectral flow cytometry, and spatial transcriptomic sequencing, we discovered that Hv1 depletion limits macrophage infiltration and enhances antigen presentation, ultimately fostering a stronger adaptive immune response. These findings establish the Hv1 channel as a crucial new immune regulator within the brain tumor milieu, offering a promising target for reprogramming macrophage function to combat glioblastoma. Funding Sources Supported by NIH R35NS132326 (LJW); Mayo Clinic Cancer Center and Mayo Clinic Center for Biomedical Discovery. Topic Categories Neuroimmunology (NEUR)
Linking immunodeficiency with lymphomagenesis: suboptimal T follicular subsets can drive DLBCL transformation 4761
Laffey, Kimberly G. , Wilton, Katelynn M. , Stiles, Robert J. , Sarker, Md Bodruzzaman, Pages, Diana Gil, Schrum, Adam G. , Schrum, Adam G , Wang, Liangyu

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.2390 Get It

Abstract Description Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy derived from transformed B cells of germinal center (GC) or post-GC origin. DLBCL incidence is elevated in immunodeficient persons with reduced T cells, such as among HIV+ patients. Yet a causal link between T cell deficiency and DLBCL is incompletely understood. Using a mouse model of spontaneous DLBCL, we show that suboptimal T cell function, but neither zero nor full T cell function, can be a driver of B cell lymphomagenesis. In CD3δ-/- mice, which exhibit reduced number, signaling, and function of T cells, we observed progressive disruption of splenic architecture and eventual DLBCL development with ∼100% incidence. In contrast, lymphoma did not develop in wild-type mice, or CD3e-/-z-/- mice with complete T cell absence. This showed that poor-but-positive suboptimal T cells were required for GC B cell transformation and outgrowth. Mechanistically, CD3δ-/- mice exhibited altered GC dynamics at steady state and in response to immunization. Compared with wild-type mice, CD3δ-/- mice had a diminished T follicular regulatory (TFR) compartment and exhibited defective T follicular helper (TFH) cell differentiation when antigen challenged, indicating compromised regulation of the GC reaction. Indeed, defective GC B cell entry and differentiation was also observed. Our data thus suggest that suboptimal function of T helper subsets can lead to dysegulated GC reactions and B cell lymphomagenesis. Funding Sources Supported by AAI Intersect Fellowship Topic Categories Immune Response Regulation: Cellular Mechanisms (IRC)
Robust Principal Component Analysis with Truncated Weighted Nuclear Norm and Adaptive Histogram Equalization: A Novel Method for Low-Quality Retinal Image Enhancement
Likassa, Habte Tadesse , Zhu, Wenhui , Dumitrascu, Oana M. , Sun, Dayu , Chen, Ding‐Geng , Chen, Kewei , Wang, Yalin

Mayo Clinic

Statistics and Data Science in Imaging | November 20, 2025 | Volume: 2 | Issue: 1 | Pages: No page available

10.1080/29979676.2025.2538438 Get It

Benefit–risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or Crohn’s disease
Vermeire, Séverine , Colombel, Jean–Frédéric, Panaccione, Remo , Beck, Kendall , Gisbert, Javier P. , Dubcenco, Elena, Klaff, Justin, Naling, Grace, Ford, Sharanya, Remple, Valencia P., Joshi, Namita , Suravaram, Smitha, Duncan, Benjamin , Wick-Urban, Bettina, Danese, Silvio , Panaccione, Remo , Chaparro, María , Gisbert, Javier P , Loftus, Edward V , Vermeire, Séverine , Danese, Silvio , Peyrin‐Biroulet, Laurent , Wang, Yibo , Loftus, Edward V.

Mayo Clinic

Journal of Crohn's and Colitis | November 19, 2025 | Volume: 20 | Issue: 1 | Pages: No page available

10.1093/ecco-jcc/jjaf198 | PMID 41264726 Get It

Abstract Background and Aims Upadacitinib (UPA)—an oral, reversible selective Janus kinase inhibitor—has a favorable benefit–risk profile for patients with Crohn’s disease (CD) and ulcerative colitis (UC). We evaluated the benefit–risk of UPA in select subgroups with CD or UC. Methods Patients were randomized to UPA 45 mg (UPA45) once daily (QD) or placebo (PBO) induction for 12 (CD: U-EXCEED, U-EXCEL) or 8 weeks (UC: U-ACHIEVE, U-ACCOMPLISH). Clinical responders were re-randomized to QD UPA 15 mg (UPA15), UPA 30 mg (UPA30), or PBO for 52-week maintenance (CD: U-ENDURE; UC: U-ACHIEVE). This exploratory post hoc analysis assessed efficacy and safety outcomes (adverse events of special interest [AESIs]: serious infections, major adverse cardiovascular [CV] events, malignancies, and venous thromboembolic events) by CV risk, prior treatment failure, and age. Results This analysis included 1021 patients with CD and 1097 with UC during induction, and 673 with CD and 746 with UC during maintenance. Improved efficacy outcomes comparable to the overall study populations were observed with UPA versus PBO across subgroups. Patients receiving UPA30 generally showed numerically higher rates of improvements versus UPA15. AESI rates were generally comparable between UPA and PBO across subgroups except for numerically higher rates of herpes zoster and serious infections in CD with UPA. Conclusions UPA resulted in consistent benefit versus placebo across CV risk, prior treatment failure, and age subgroups. No treatment differences were seen in AESIs across subgroups except herpes zoster and serious infections, reinforcing the favorable benefit–risk profile for UPA in CD and UC seen in the overall study populations. Clinical trial numbers NCT02819635, NCT03653026, NCT03345836, NCT03345849, NCT03345823
Multidimensional Single-Cell Transcriptomic Profiling of Uterine Leiomyosarcomas Reveals Distinct Tumor States with Inferred Therapeutic Vulnerabilities
Korah, Maria, Agolia, James Paul , Reddy, Biren , Flojo, Renceh A. B., Wang, Lilin , Bethi, Rishik, Bobst, Wesley, Liang, Brooke, Yip, Kaylin A., Tabora, Angela D, Hsu, Chia-Hsin, Reveron‐Thornton, Rosyli F. , Guo, Chuner, Delitto, Andrea E., Xie, Peter Y., Tomasso, Antonio, Daniel, Sara K. , Litkouhi, Babak , Moding, Everett J. , Poultsides, George A. , Norton, Jeffrey A. , Charville, Gregory W. , Ganjoo, Kristen N. , Lee, Byrne , Longaker, Michael T., Gonçalves, Amanda Costa , Bethi, Rishik, Liang, Brooke, Yip, Kaylin A., Hsu, Chia-Hsin, Guo, Chuner, Gruener, Robert F. , Xie, Peter Y., Tomasso, Antonio, Sun, Beatrice J. , Dorigo, Oliver , Bui, Nam Q. , Pan, Minggui , Kalbasi, Anusha K. , Kirane, Amanda , Newman, Aaron M. , Foster, Deshka S. , Huang, R. Stephanie , Delitto, Daniel

Mayo Clinic

No container title available | November 18, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.11.17.688894 Get It

Abstract Uterine leiomyosarcoma (ULMS) is an orphan disease that frequently recurs and metastasizes, with patients undergoing multiple lines of chemotherapy due to lack of effective therapeutic targets. To address this gap, we used single-cell RNA sequencing and spatial transcriptomic analysis to comprehensively profile ULMS. We uncovered multiple states of tumor cells, including tumor cells with mesenchyme-like features, ischemic tumor cells defined by a MYC program, inflammatory tumor cells with active interferon signaling, and stem cell-like hormone receptor-positive cells. The inferred spatial correlates of these tumor cell states demonstrated unique localization patterns. By correlating these signatures to bulk RNA sequencing data, we demonstrate the relevance of these findings to clinical outcomes. Finally, using the single-cell integration and drug response prediction algorithm (scIDUC), we propose drug predictions that may target specific tumor states. Our findings suggest new avenues for further exploration of individualized and multifaceted therapeutic strategies to treat ULMS.
Natural history of asymptomatic moderate or severe aortic regurgitation: a systematic review and meta-analysis
Naser, Jwan A. , Massad, Faysal, Al‐Abcha, Abdullah , Gerberi, Dana , Pislaru, Sorin V. , Nkomo, Vuyisile T. , Thaden, Jeremy J. , Wang, Zhen , Pellikka, Patricia A. , Pellikka, Patricia A , Michelena, Hector I , Enriquez-Sarano, Maurice , Sabbah, Michael S. , Nkomo, Vuyisile T , Al-Abcha, Abdulah , Naser, Jwan A , Cavalcante, João L. , Michelena, Héctor I. , Enriquez‐Sarano, Maurice

Mayo Clinic

Heart | November 17, 2025 | Volume: 112 | Issue: 12 | Pages: 646-657

10.1136/heartjnl-2025-326643 | PMID 41249036 Get It

Background The natural history of asymptomatic moderate or severe aortic regurgitation (AR) remains uncertain, with conflicting reports about its progression and surgical timing. We aimed to quantify adverse outcomes under conservative management and evaluate the association of aortic valve replacement/repair (AVR) with mortality. Methods Systematic searches (inception–July 2025) identified cohort studies of asymptomatic moderate/severe AR. Random-effects models estimated pooled incidence rates of adverse events; fixed-effects models were used for hazard ratios (HRs) of AVR vs conservative management. Results Twenty-seven studies (4720 patients; mean age 49 years; mean follow-up 3.9 years) were included. Pooled incidence rates per 100 person-years were 1.75 (95% CI 1.27 to 2.41) for all-cause mortality, 1.29 for cardiac death, 0.29 for sudden death, 4.30 for new symptoms and 7.01 for AVR. Asymptomatic low left ventricular ejection fraction occurred in only 0.9 per 100 person-years. Mortality rates were more than double those of the general population across age groups—2.45 (1.90 to 3.18) per 100 person-years for cohorts with mean age ≥50 years versus 0.59 (0.29 to 1.21) for younger cohorts. Early AVR was associated with lower mortality (pooled HR 0.33; 95% CI 0.30 to 0.37). Conclusion Asymptomatic moderate/severe AR carries significant excess mortality irrespective of age, contradicting its historically benign reputation. Given the rarity of asymptomatic LV dysfunction, earlier intervention guided by more sensitive markers of LV damage may improve outcomes, although heterogeneity and study quality warrant cautious interpretation. PROSPERO registration number CRD42024522683.
New-Onset Psychiatric Disorders After Lumbar Fusion: Predictors, Timing, and Risk Stratification
Ballatori, Alexander M. , Ton, Andy , Chen, Xiao T. , Buser, Zorica , Wang, Jeffrey , Ton, Andy , Buser, Zorica , Shahrestani, Shane

Mayo Clinic

Global Spine Journal | November 17, 2025 | Volume: 16 | Issue: 5 | Pages: 2212-2219

10.1177/21925682251400284 | PMID 41246798 Get It

Study Design Retrospective cohort study using a nationally representative inpatient database. Objective To determine the incidence, timing, and predictors of new-onset psychiatric disorders following lumbar fusion surgery, and to propose a data-driven risk stratification model for early identification and intervention. Methods We queried the Nationwide Readmissions Database (2016-2019) to identify adults undergoing elective inpatient lumbar fusion. Patients with preexisting psychiatric diagnoses were excluded. Outcomes included new-onset depression, anxiety, suicidal ideation, and homicidal ideation within 12 months postoperatively. Predictors were assessed using odds ratios. Timing of onset was evaluated with density plots. Results Among 839,576 patients, 12,011 developed depression, 11,828 anxiety, 916 suicidal ideation, and 63 homicidal ideation. Most diagnoses occurred within 90 days postoperatively, with peak incidence around 3 weeks. Opioid use during the index admission significantly increased odds of suicidal ideation (OR 2.13, P = 0.001), anxiety (OR 1.26, P = 0.002), and showed a trend toward depression (OR 1.14, P = 0.087). Medicaid insurance was the strongest predictor of suicidal (OR 3.69) and homicidal ideation (OR 6.41). Female sex and younger age were associated with anxiety and depression; older age was protective against ideation. Conclusions New-onset psychiatric disorders are a frequent and early complication following lumbar fusion. Several modifiable and demographic factors - including perioperative opioid use and socioeconomic status - significantly predict risk. These findings underscore the need for structured mental health screening within the first 3 months post-surgery. Implementing a predictive risk stratification tool could enable earlier psychiatric referral, reduce long-term morbidity, and improve both recovery trajectories and overall quality of life.
A framework for using DNA methylation-based modelling for the clinical management of cranial meningioma
Landry, Alexander , Wang, Justin Z. , Patil, Vikas, Ajisebutu, Andrew, Gui, Chloe , Yefet, Leeor, Mamatjan, Yasin , Wei, Qingxia , Singh, Olivia, Mansouri, Sheila , Ehret, Felix , Capper, David , Cohen-Gadol, Aaron A, Behling, Felix , Sloan, Andrew E. , Chambless, Lola B. , Makarenko, Serge , Yip, Stephen , Tsang, Derek S. , Gao, Andrew , Aldape, Kenneth , Nassiri, Farshad , Zadeh, Gelareh , Santarius, Thomas , Selman, Warren R., Couce, Marta , Wen, Patrick Y. , Walbert, Tobias , Felicella, Michelle M. , Brodie, Chaya , Snyder, James P., Saladino, Andrea , Schichor, Christian , Tonn, Jörg‐Christian, Goldbrunner, Roland , Timmer, Marco , Schimdt, Nils Ole, Jenkinson, Michael D. , Millward, Christopher P. , Islim, Abdurrahman I. , Fl, Behling, Santacroce, Antonio , Schittenhelm, Jens , Raleigh, David R. , Butowski, Nicholas , Westphal, Manfred , Lamszus, Katrin , Mawrin, Christian , Kurz, Sylvia C. , Zada, Gabriel , Yip, Stephen, Zherebitskiy, Viktor, Hnenny, Luke, Dunn, Ian F. , Moliterno, Jennifer , McDermott, Michael , Vogelbaum, Michael A. , Aldape, Kenneth, Alkividias, Tzannis, Short, Susan , Bos, Eelke M. , Dincer, Alper , Paßlack, Peter, Ehret, Felix, Lopez, Clara, Arvaniti, Christina , Benjamin, Carolina , Jackson, Christina , Jeyaretna, Sanjeeva, Scartoni, Daniele , Amelio, Dante , Ivanidze, Jana , Kien, Duong Trung, Millareschavez, Miguel, AlThgafi, Malak, LeRhun, Emilie, Smee, Robert, Muirhead, William , Molina, Eric Suero, Julius, Vitowanu, Chen, J., Mrugała, Maciej M. , Castro, Ana Valeria , Mamatjan, Yasin , Capper, David , Tatagiba, Marcos , Barnholtz-Sloan, Jill S , Yip, Stephen , Aldape, Kenneth , Zadeh, Gelareh , Short, Susan C , Yefet, Leeor S. , Ellenbogen, Yosef , Liu, Jeff , Singh, Olivia , Tabatabai, Ghazaleh , Tatagiba, Marcos , Barnholtz‐Sloan, Jill S. , Mansouri, Alireza , Brastianos, Priscilla K. , Shih, Helen A. , Bi, Wenya Linda , Huang, Raymond Y. , Wen, Patrick Yung , Lee, Ian , Malta, Tathiane Maistro , Castro, Ana Valéria , Noushmehr, Houtan , DiMeco, Francesco , Pollo, Bianca , Kaufmann, Timothy J. , Lachance, Daniel Honore , Giannini, Caterina , Galanis, Evanthia , Raghunathan, Aditya , Hanemann, C. Oliver , Au, Karolyn , Galldiks, Norbert , Herold‐Mende, Christel C. , Sahm, Felix , Jungk, Christine , Jungwirth, Gerhard , Deimling, Andreas von , Drummond, Katharine Jann , Morokoff, Andrew P. , Renovanz, Mirjam , Fougère, Christian la , Perry, Arie , Ricklefs, Franz , Horbinski, Craig , Ng, Ho‐Keung , Snuderl, Matija , Sulman, Erik P. , Cohen‐Gadol, Aaron , Javadpour, Mohsen , Fountain, Daniel Mark , Mathiesen, Tiit Illimar , Pathmanaban, Omar Nathan , Boutros, Paul C. , Fountas, Konstantinos N. , Walsh, Kyle M. , Carvalho, Bruno , Maas, Sybren L. N. , Deng, Maximilian Y. , Mehta, Minesh P. , Odia, Yazmín , Everson, Richard G. , Balogun, James , Calabrese, Evan , Karschnia, Philipp , Teske, Nico , Fariselli, Laura , Greve, Tobias , Ivan, Michael E , Palmer, Joshua D. , Ostrom, Quinn T. , Youngblood, Mark W. , Emerson, Sam, Weller, Michael , Martínez-Pérez, Rafael , Mukherjee, Raj, Cervio, Andrés , Turner, Clinton P. , Chen, Jiawei, Karmur, Brij S. , Neth, Bryan J.

Mayo Clinic

Neuro-Oncology | November 15, 2025 | Volume: 28 | Issue: 2 | Pages: 430-439

10.1093/neuonc/noaf237 | PMID 41259653 Get It

Abstract Background DNA methylation profiling can be used to robustly predict postsurgical outcomes and response to radiotherapy (RT) for meningioma patients. To allow for seamless integration of these complementary models into clinical practice, a practical framework is needed. Methods We leveraged a cohort of nearly 2000 surgically-treated meningiomas with DNA methylation profiling and clinical outcomes data. Existing methylation-based prediction models were dichotomized to yield four risk groups: low and high recurrent risk, each with RT sensitive and resistant subgroups. Risk groups were correlated with progression-free survival in the context of existing biomarkers including extent of resection and WHO grade. Results We first demonstrated that all risk groups benefit from gross total resection. All “high-risk, RT sensitive” tumors (n = 306, 15.7%) also benefited from adjuvant RT: after GTR, median PFS increased from 4.68 (4.13-9.48) years to not reached (P = .003); after subtotal resection (STR), from 2.12 (1.59-3.02) to 4.09 (3.41-not reached) years (P = .004). “Low-risk, RT sensitive cases” (n = 1207, 61.8%) also benefited from RT after STR (median PFS 7.39 (6.66-12.8) vs. 16.53 (10.35-not reached) years, P = .03), suggesting that RT be considered in these patients. Neither “low-risk RT resistant” (n = 84, 4.3%) nor “high-risk RT resistant” (n = 356, 18.2%) cases benefited from RT, and the latter group was associated with universally poor outcomes. Conclusions We identify methylation-defined risk groups of meningioma for which additional benefit is gained from adjuvant RT, leading to a clinical decision-making framework for straightforward integration of molecular models into clinical practice.
Chronic myelomonocytic leukemia in the young (aged 50 years and younger): Divergent clinical and molecular characteristics from the elderly
Ok, Chi Young , Natu, Anuya , Fathalla, Lamiaa A. , Symes, Emily , Barone, Paul , Shestakova, Anna , Foucar, Kathryn , Bueso‐Ramos, Carlos E. , Montalban‐Bravo, Guillermo , Patnaik, Mrinal M. , Hasserjian, Robert P. , Geyer, Julia T. , Bagg, Adam , Reichard, Kaaren K. , Wang, Sa A. , Bravo, Guillermo Montalban , Daneshpajouhnejad, Parnaz , Orazi, Attilio , Arber, Daniel A.

Mayo Clinic

Cancer | November 14, 2025 | Volume: 131 | Issue: 22 | Pages: No page available

10.1002/cncr.70176 | PMID 41236405 Get It

ABSTRACT Background Chronic myelomonocytic leukemia (CMML) is largely a disease of individuals older than 50 years; its occurrence in patients aged 50 years and younger is rare. The authors sought to characterize the clinicopathologic features and genetic profile of young‐onset (age 50 years and younger) CMML (y‐CMML) compared with older onset (older than 50 years) CMML (o‐CMML). Methods The authors conducted a multi‐institutional study of 32 patients with y‐CMML and 119 patients with o‐CMML, analyzing clinical, morphologic, cytogenetic, and molecular data. Results Patients who had y‐CMML frequently presented with splenomegaly (59% vs. 11%; p < .001) and hepatomegaly (25% vs. 2%; p < .001) compared with those who had o‐CMML. Although the overall incidence of cytogenetic abnormalities was similar, patients who had y‐CMML exhibited distinct mutational patterns. PTPN11 mutations were significantly more common in y‐CMML (13% vs. 3%; p = .034) than in o‐CMML, whereas TET2 (6% vs. 57%; p < .001) and SRSF2 (16% vs. 46%; p = .002) mutations were significantly less frequent. In addition, multi‐hit TET2 (6% vs. 34%; p = .002) and TET2‐SRSF2 (3% vs. 29%; p = .003) co‐mutations were rare in y‐CMML. However, the molecular differences did not affect the CMML‐specific risk‐stratification categories because the clinical outcomes, including overall survival and leukemia‐free survival, did not differ between the two groups. Conclusions CMML in patients aged 50 years and younger is rare and presents with unique clinical and mutational features, suggesting a distinct pathogenesis.